News
Context Therapeutics Expands Board of Directors
Company Adds Richard Berman, Jennifer Evans Stacey and Linda West to Board
Context Therapeutics Announces First Patient Dosed in Window of Opportunity Study
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.
Context Therapeutics Announces IND Clearance for ONA-XR in 2L/3L Metastatic Breast Cancer
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.